Mariner’s Apogee Therapeutics APGE Stock Holding History

Mariner’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,101	Closed	-$687K	–	3558
2025 Q4	$687K	Buy	9,101 +3,224	+55%	+$203K	﹤0.01%	2225
2025 Q3	$233K	Sell	5,877 -3,390	-37%	-$129K	﹤0.01%	3033
2025 Q2	$402K	Buy	+9,267	New	+$353K	﹤0.01%	2500

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Mariner's APGE Position: Q1 2026 in Review

Mariner sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 9,101 shares — an estimated $687K sold.

Mariner first reported a position in APGE in Q2 2025 and held it in 3 quarters. The position peaked at $687K in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Mariner reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
Mariner sold 9,101 Apogee Therapeutics shares in Q1 2026, an estimated $687K.
Mariner first reported a position in Apogee Therapeutics in Q2 2025 and held it in 3 quarters.
Mariner's Apogee Therapeutics position peaked at $687K in Q4 2025.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.